{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:35:07Z","timestamp":1789011307455,"version":"build-2803163510"},"reference-count":216,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Camden Research Initiative fund"},{"name":"New Jersey Health Foundation"},{"name":"Cooper Medical School of Rowan University, Camden, NJ"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments.<\/jats:p>","DOI":"10.3390\/ph16030415","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T02:01:47Z","timestamp":1678327307000},"page":"415","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Past, Present, and a Glance into the Future of Multiple Myeloma Treatment"],"prefix":"10.3390","volume":"16","author":[{"given":"Weam Othman","family":"Elbezanti","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School of Rowan University, 401S Broadway, Camden, NJ 08103, USA"},{"name":"Department of Hematology, MD Anderson Cancer Center at Cooper, Cooper Health System, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore B.","family":"Challagundla","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, The Fred and Pamela Buffett Cancer Center, The Child Health Research Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5234-1235","authenticated-orcid":false,"given":"Subash C.","family":"Jonnalagadda","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Rowan University, Glassboro, NJ 08028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6498-9119","authenticated-orcid":false,"given":"Tulin","family":"Budak-Alpdogan","sequence":"additional","affiliation":[{"name":"Department of Hematology, MD Anderson Cancer Center at Cooper, Cooper Health System, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2767-2929","authenticated-orcid":false,"given":"Manoj K.","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School of Rowan University, 401S Broadway, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-018-0144-x","article-title":"Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma","volume":"8","author":"Atrash","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1038\/leu.2016.366","article-title":"Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma","volume":"31","author":"Mithraprabhu","year":"2017","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/2643-3230.BCD-20-0170","article-title":"Promiscuous Structural Variants Drive Myeloma Initiation and Progression","volume":"1","author":"Bergsagel","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas-current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","article-title":"The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance","volume":"14","author":"Meads","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.ejca.2005.12.026","article-title":"Signalling and survival pathways in multiple myeloma","volume":"42","author":"Bommert","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.leukres.2012.02.016","article-title":"Interleukin-6, osteopontin and Raf\/MEK\/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines","volume":"36","author":"Yosifov","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/sj.leu.2403970","article-title":"Growth factors and antiapoptotic signaling pathways in multiple myeloma","volume":"19","author":"Lokhorst","year":"2005","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2017.197","article-title":"The bone-marrow niche in MDS and MGUS: Implications for AML and MM","volume":"15","author":"Ghobrial","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","author":"Pawlyn","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Neumeister, P., Schulz, E., Pansy, K., Szmyra, M., and Deutsch, A.J. (2022). Targeting the Microenvironment for Treating Multiple Myeloma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147627"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"60698","DOI":"10.18632\/oncotarget.10849","article-title":"Microenvironment drug resistance in multiple myeloma: Emerging new players","volume":"7","author":"Desantis","year":"2016","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.ejca.2005.12.025","article-title":"The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions","volume":"42","author":"Mitsiades","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V82.12.3712.3712","article-title":"Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion","volume":"82","author":"Uchiyama","year":"1993","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1084\/jem.184.3.1101","article-title":"A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)","volume":"184","author":"Bleul","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/cmi.2017.107","article-title":"The unique structural and functional features of CXCL12","volume":"15","author":"Janssens","year":"2018","journal-title":"Cell Mol. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1073\/pnas.95.16.9448","article-title":"Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice","volume":"95","author":"Ma","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1593\/neo.09272","article-title":"CXCR4 regulates the early extravasation of metastatic tumor cells in vivo","volume":"11","author":"Gassmann","year":"2009","journal-title":"Neoplasia"},{"key":"ref_24","first-page":"539","article-title":"The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma","volume":"1","author":"Hideshima","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","article-title":"The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/bjh.14807","article-title":"CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma","volume":"179","author":"Waldschmidt","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"19702","DOI":"10.1002\/jcp.28570","article-title":"Blockade of SDF-1\/CXCR4 reduces adhesion-mediated chemoresistance of multiple myeloma cells via interacting with interleukin-6","volume":"234","author":"Liu","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/cas.12414","article-title":"MGr1-Ag\/37LRP induces cell adhesion-mediated drug resistance through FAK\/PI3K and MAPK pathway in gastric cancer","volume":"105","author":"Sun","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1158\/1535-7163.MCT-06-0684","article-title":"Wnt3\/RhoA\/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism","volume":"6","author":"Kobune","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood-2003-12-4218","article-title":"The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase","volume":"104","author":"Schmidmaier","year":"2004","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00109-015-1345-4","article-title":"Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities","volume":"94","author":"Shay","year":"2016","journal-title":"J. Mol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Chong, P.S.Y., Chng, W.J., and de Mel, S. (2019). STAT3: A Promising Therapeutic Target in Multiple Myeloma. Cancers, 11.","DOI":"10.3390\/cancers11050731"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: New and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1158\/0008-5472.CAN-10-0736","article-title":"Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells","volume":"70","author":"Herrmann","year":"2010","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9599","DOI":"10.1158\/0008-5472.CAN-10-1293","article-title":"Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects","volume":"70","author":"Kujawski","year":"2010","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.CCR-18-1537","article-title":"Role of the RANK\/RANKL Pathway in Multiple Myeloma","volume":"25","author":"Raje","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1537-2995.2005.04222.x","article-title":"Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist","volume":"45","author":"Liles","year":"2005","journal-title":"Transfusion"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood-2005-02-0468","article-title":"The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone","volume":"106","author":"Flomenberg","year":"2005","journal-title":"Blood"},{"key":"ref_39","first-page":"87","article-title":"Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806)","volume":"21","author":"Bergsagel","year":"1962","journal-title":"Cancer Chemother Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood.V30.1.74.74","article-title":"Melphalan in multiple myeloma","volume":"30","author":"Hoogstraten","year":"1967","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: Analysis of 1175 patients","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000206984","article-title":"Identical twin marrow transplantation in multiple myeloma","volume":"68","author":"Osserman","year":"1982","journal-title":"Acta Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jnci\/95.12.845","article-title":"First proteasome inhibitor approved for multiple myeloma","volume":"95","author":"Twombly","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"Schlag","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_49","unstructured":"Services USDoHaH (2023, March 01). Hematology\/Oncology (Cancer) Approvals & Safety Notifications: Previous News Items; U.S. Food and Drug Administration, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/oncology-cancer-hematologic-malignancies-approval-notifications."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/bmt.2014.196","article-title":"Plerixafor in patients with lymphoma and multiple myeloma: Effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization","volume":"50","author":"Querol","year":"2015","journal-title":"Bone Marrow Transpl."},{"key":"ref_54","unstructured":"Administration USFaD (2023, March 01). Carfilzomib, Available online: http:\/\/wayback.archive-it.org\/7993\/20170113081106\/http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm312945.htm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: A randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_61","unstructured":"Sanofi (2023, March 01). Sanofi: FDA Approves Sarclisa\u00ae (isatuximab-irfc) for Patients with Relapsed Refractory Multiple Myeloma. Available online: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2020\/2020-03-02-18-51-16-1993727."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/asheducation.V2014.1.255.3885263","article-title":"Early or delayed transplantation for multiple myeloma in the era of novel therapy: Does one size fit all?","volume":"2014","author":"Richardson","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic value of minimal residual disease negativity in myeloma: Combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41571-019-0198-0","article-title":"MAIA under the microscope-bringing trial design into focus","volume":"16","author":"Kapoor","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/S2352-3026(16)30147-8","article-title":"Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): A randomised, placebo-controlled, phase 3 trial","volume":"3","author":"Hungria","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.14549","article-title":"Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: Secondary analysis from the phase 3 ASPIRE study","volume":"177","author":"Dimopoulos","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: Final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bjh.14787","article-title":"Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth","volume":"178","author":"Dimopoulos","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ajh.26172","article-title":"Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma","volume":"96","author":"Auner","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","article-title":"Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma","volume":"36","author":"Vogl","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1074\/jbc.273.11.6373","article-title":"Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis","volume":"273","author":"Meriin","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0014-5793(01)02770-3","article-title":"Proteasome inhibitors induce Fas-mediated apoptosis by c-Myc accumulation and subsequent induction of FasL message in human glioma cells","volume":"504","author":"Tani","year":"2001","journal-title":"FEBS Lett."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"33714","DOI":"10.1074\/jbc.M302559200","article-title":"Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells","volume":"278","author":"Ling","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341","volume":"101","author":"Hideshima","year":"2003","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Ito, S. (2020). Proteasome Inhibitors for the Treatment of Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12020265"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"A Practical Review of Proteasome Pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"ref_88","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/onc.2008.385","article-title":"Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma","volume":"28","author":"Kikuchi","year":"2009","journal-title":"Oncogene"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2147\/CMAR.S150653","article-title":"Carfilzomib for relapsed and refractory multiple myeloma","volume":"11","author":"Groen","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-142274","article-title":"Efficacy of Ixazomib and Bortezomib with Lenalidomide Combination Regimens for Multiple Myeloma: A Systematic Review","volume":"136","author":"Sana","year":"2020","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Udeshi","year":"2014","journal-title":"Science"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13045-017-0529-5","article-title":"Role of protein kinases CK1\u03b1 and CK2 in multiple myeloma: Regulation of pivotal survival and stress-managing pathways","volume":"10","author":"Manni","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.18632\/oncotarget.14654","article-title":"Inactivation of CK1\u03b1 in multiple myeloma empowers drug cytotoxicity by affecting AKT and \u03b2-catenin survival signaling pathways","volume":"8","author":"Manni","year":"2017","journal-title":"Oncotarget"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2010-01-266320","article-title":"A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway","volume":"118","author":"Zheng","year":"2011","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"6722","DOI":"10.1158\/0008-5472.CAN-05-3758","article-title":"Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells","volume":"66","author":"Yu","year":"2006","journal-title":"Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood.V112.11.2761.2761","article-title":"Opposing Effects of Dexamethasone on Lenalidomide Activity in Multiple Myeloma: Additive\/Synergistic Effects on Anti-Proliferative Activity on Myeloma Cells and Antagonistic Effects on Immune Function","volume":"112","author":"Schafer","year":"2008","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood-2016-09-738500","article-title":"p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma","volume":"129","author":"Hideshima","year":"2017","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset","volume":"187","author":"Haslett","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V116.21.492.492","article-title":"Lenalidomide Decreases PD-1 Expression, Depletes Regulatory T-Cells and Improves Cellular Response to a Multiple Myeloma\/Dendritic Cell Fusion Vaccine In Vitro","volume":"116","author":"Luptakova","year":"2010","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","article-title":"Lenalidomide enhances anti-myeloma cellular immunity","volume":"62","author":"Luptakova","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.exphem.2012.11.005","article-title":"Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL\/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules","volume":"41","author":"Bolzoni","year":"2013","journal-title":"Exp. Hematol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ymgme.2016.06.013","article-title":"CBP\/p300 acetyltransferase activity in hematologic malignancies","volume":"119","author":"Dutta","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4161\/15592294.2014.983367","article-title":"Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma","volume":"9","author":"Mithraprabhu","year":"2014","journal-title":"Epigenetics"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1182\/blood-2010-05-284414","article-title":"Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists","volume":"116","author":"Mandawat","year":"2010","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"13162","DOI":"10.1073\/pnas.1608067113","article-title":"Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma","volume":"113","author":"Hideshima","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2013.03.016","article-title":"Histone deacetylase inhibitors in multiple myeloma: Rationale and evidence for their use in combination therapy","volume":"13","author":"Kaufman","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Imai, Y., Hirano, M., Kobayashi, M., Futami, M., and Tojo, A. (2019). HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action. Cancers, 11.","DOI":"10.3390\/cancers11040475"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Castella, M., Fern\u00e1ndez de Larrea, C., and Mart\u00edn-Antonio, B. (2018). Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113613"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"Raman","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.leukres.2013.12.007","article-title":"Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases","volume":"38","author":"Tembhare","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1365-2141.2010.08121.x","article-title":"Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders","volume":"149","author":"Raja","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cyto.b.21279","article-title":"Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents","volume":"90","author":"Muccio","year":"2016","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: More room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: A (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): Part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.3324\/haematol.2021.279459","article-title":"Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","volume":"107","author":"Usmani","year":"2022","journal-title":"Haematologica"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1007\/s12325-021-01884-7","article-title":"DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor\u2009+\u2009Dexamethasone and Standard of Care Treatments in Relapsed\/Refractory Multiple Myeloma","volume":"38","author":"Prawitz","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"LBA-6","DOI":"10.1182\/blood-2019-132629","article-title":"Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1002\/ajh.26434","article-title":"Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study","volume":"97","author":"Delimpasi","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","article-title":"FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.2217\/fon-2019-0431","article-title":"Isatuximab plus carfilzomib\/dexamethasone versus carfilzomib\/dexamethasone in patients with relapsed\/refractory multiple myeloma: IKEMA Phase III study design","volume":"16","author":"Moreau","year":"2020","journal-title":"Future Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-135874","article-title":"Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Dimopoulos","year":"2020","journal-title":"Blood"},{"key":"ref_138","unstructured":"Drug USFa (2023, March 01). FDA Approves Darzalex Faspro, Kyprolis, and Dexamethasone for Multiple Myeloma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-darzalex-faspro-kyprolis-and-dexamethasone-multiple-myeloma."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11523-022-00893-y","article-title":"Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma","volume":"17","author":"Girgis","year":"2022","journal-title":"Target Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.critrevonc.2013.04.003","article-title":"CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma","volume":"88","author":"Veillette","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/1535-7163.MCT-17-0998","article-title":"Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab","volume":"17","author":"Kurdi","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41375-019-0525-6","article-title":"Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7","volume":"34","author":"Kikuchi","year":"2020","journal-title":"Leukemia"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/joim.12470","article-title":"The immune system and cancer evasion strategies: Therapeutic concepts","volume":"279","author":"Muenst","year":"2016","journal-title":"J. Intern. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/13543784.2021.1955103","article-title":"Immune checkpoint inhibitors for the treatment of myeloma: Novel investigational options","volume":"30","author":"Moreau","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma","volume":"21","author":"Samur","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1027385","DOI":"10.3389\/fimmu.2022.1027385","article-title":"Immunotherapy for the treatment of multiple myeloma","volume":"13","author":"Boussi","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/bjh.15888","article-title":"Phase 1b trial of pembrolizumab monotherapy for relapsed\/refractory multiple myeloma: KEYNOTE-013","volume":"186","author":"Ribrag","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","article-title":"Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma","volume":"123","author":"Shpilberg","year":"2014","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.23868","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"90","author":"Orlowski","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","article-title":"Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma","volume":"25","author":"Brighton","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-Drug Conjugate-Based Therapeutics: State of the Science","volume":"111","author":"Birrer","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6004\/jadpro.2022.13.1.7","article-title":"Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed\/Refractory Multiple Myeloma","volume":"13","author":"Ketchum","year":"2022","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.2147\/DDDT.S267404","article-title":"Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety","volume":"15","author":"Offidani","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1126\/science.170.3956.447","article-title":"Specific inhibition of nuclear RNA polymerase II by alpha-amanitin","volume":"170","author":"Lindell","year":"1970","journal-title":"Science"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ddtec.2018.08.005","article-title":"Amanitins and their development as a payload for antibody-drug conjugates","volume":"30","author":"Pahl","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2008.04.023","article-title":"The RNA polymerase II trigger loop functions in substrate selection and is directly targeted by alpha-amanitin","volume":"30","author":"Kaplan","year":"2008","journal-title":"Mol. Cell"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: A mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/d41573-022-00040-2","article-title":"Bispecific antibodies in oncology","volume":"21","author":"Esfandiari","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1182\/blood-2022-162738","article-title":"Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort","volume":"140","author":"Grosicki","year":"2022","journal-title":"Blood"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1179\/1607845413Y.0000000079","article-title":"GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells","volume":"18","author":"Cohen","year":"2013","journal-title":"Hematology"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40164-020-00190-2","article-title":"Engineering better chimeric antigen receptor T cells","volume":"9","author":"Zhang","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jocit.2016.08.001","article-title":"Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective","volume":"2","author":"Smith","year":"2016","journal-title":"J. Cell. Immunother."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma","volume":"1","author":"Staehr","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","article-title":"A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers","volume":"13","author":"Wong","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Fan, F.X.-H., Zhao, W.-h., Liu, J., He, A., Chen, Y.-X., Cao, X.-m., Yang, N., Wang, B., Zhang, P., and Zhang, Y. (2017). Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory\/relapsed multiple myeloma. J. Clin. Oncol., 35.","DOI":"10.1200\/JCO.2017.35.15_suppl.LBA3001"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.35.15_suppl.3010","article-title":"First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: Updated results","volume":"35","author":"Berdeja","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3389\/fimmu.2017.01444","article-title":"Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs","volume":"8","author":"Pittari","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41417-021-00365-x","article-title":"CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model","volume":"29","author":"Ng","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/MOH.0000000000000698","article-title":"Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes","volume":"29","author":"Shimony","year":"2022","journal-title":"Curr. Opin. Hematol."},{"key":"ref_179","unstructured":"FDA.gov (2023, March 01). FDA Approves Venetoclax for CLL and SLL, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-venetoclax-cll-and-sll."},{"key":"ref_180","unstructured":"ClinicalTrials.gov (2023, March 01). Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=Myeloma&term=Venetoclax&cntry=&state=&city=&dist=."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","article-title":"Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting","volume":"3","author":"Slomp","year":"2019","journal-title":"Blood Adv."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2141.2006.06481.x","article-title":"Abnormalities of chromosome 1p\/q are highly associated with chromosome 13\/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma","volume":"136","author":"Wu","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","article-title":"Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival","volume":"19","author":"Robillard","year":"2005","journal-title":"Leukemia"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4161\/cib.21554","article-title":"Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors","volume":"5","author":"Liu","year":"2012","journal-title":"Commun. Integr. Biol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"699629","DOI":"10.3389\/fphar.2021.699629","article-title":"Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma","volume":"12","author":"Chitren","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_190","unstructured":"ClinicalTrials.gov (2023, March 01). Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02992483?term=MIK665&cond=myeloma&draw=2&rank=1."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1538-7445.AM2019-4482","article-title":"Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models","volume":"79","author":"Maragno","year":"2019","journal-title":"Cancer Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1158\/1538-7445.AM2019-4477","article-title":"Abstract 4477: MIK665\/S64315, a novel Mcl-1 inhibitor, in combination with Bcl-2 inhibitors exhibits strong synergistic antitumor activity in a range of hematologic malignancies","volume":"79","author":"Halilovic","year":"2019","journal-title":"Cancer Res."},{"key":"ref_193","unstructured":"ClinicalTrials.gov (2023, March 01). VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed\/Refractory Non-Hodgkin Lymphoma, Relapsed\/Refractory Acute Myeloid Leukemia, or Relapsed\/Refractory Multiple Myeloma), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04702425."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"10224","DOI":"10.1074\/jbc.M111.334532","article-title":"Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation","volume":"287","author":"Doi","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Pandey, M.K., Gowda, K., Doi, K., Sharma, A.K., Wang, H.G., and Amin, S. (2013). Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0078570"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"35466","DOI":"10.18632\/oncotarget.8154","article-title":"Multiple myeloma cancer stem cells","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.18632\/oncotarget.1145","article-title":"Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival","volume":"4","author":"Reghunathan","year":"2013","journal-title":"Oncotarget"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.2015.138826","article-title":"The myeloma stem cell concept, revisited: From phenomenology to operational terms","volume":"101","author":"Johnsen","year":"2016","journal-title":"Haematologica"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1756-8722-6-91","article-title":"Fact or fiction--identifying the elusive multiple myeloma stem cell","volume":"6","author":"Kellner","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.7314\/APJCP.2013.14.12.7179","article-title":"Scutellaria extract decreases the proportion of side population cells in a myeloma cell line by down-regulating the expression of ABCG2 protein","volume":"14","author":"Lin","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7164\/antibiotics.27.814","article-title":"Salinomycin, a new polyether antibiotic","volume":"27","author":"Miyazaki","year":"1974","journal-title":"J. Antibiot."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.bbrc.2010.03.138","article-title":"Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells","volume":"394","author":"Fuchs","year":"2010","journal-title":"Biochem. Biophys Res. Commun."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood.V116.21.1574.1574","article-title":"Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor\u2013Microenvironment Interactions","volume":"116","author":"Kastritis","year":"2010","journal-title":"Blood"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/bs.pmbts.2019.03.008","article-title":"Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer\u2019s source","volume":"164","author":"Ruiu","year":"2019","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","article-title":"ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome","volume":"1","author":"Ginestier","year":"2007","journal-title":"Cell Stem. Cell"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/leu.2013.383","article-title":"ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma","volume":"28","author":"Zhou","year":"2014","journal-title":"Leukemia"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"11986","DOI":"10.18632\/oncotarget.2388","article-title":"NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma","volume":"5","author":"Yang","year":"2014","journal-title":"Oncotarget"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.tips.2019.08.002","article-title":"Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics","volume":"40","author":"Dinavahi","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.exphem.2014.07.261","article-title":"Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways","volume":"42","author":"Pandey","year":"2014","journal-title":"Exp. Hematol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/0008-5472.CAN-14-2362","article-title":"Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma","volume":"75","author":"Yang","year":"2015","journal-title":"Cancer Res."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Von Suskil, M., Sultana, K.N., Elbezanti, W.O., Al-Odat, O.S., Chitren, R., Tiwari, A.K., Challagundla, K.B., Srivastava, S.K., Jonnalagadda, S.C., and Budak-Alpdogan, T. (2021). Bruton\u2019s Tyrosine Kinase Targeting in Multiple Myeloma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115707"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1126\/science.271.5250.822","article-title":"Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases","volume":"271","author":"Rawlings","year":"1996","journal-title":"Science"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"894535","DOI":"10.3389\/fphar.2022.894535","article-title":"Development of a novel Bruton\u2019s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells","volume":"13","author":"Elbezanti","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-022-01597-y","article-title":"Clonal evolution after treatment pressure in multiple myeloma: Heterogenous genomic aberrations and transcriptomic convergence","volume":"36","author":"Misund","year":"2022","journal-title":"Leukemia"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/3\/415\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:51:24Z","timestamp":1760122284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/3\/415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":216,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ph16030415"],"URL":"https:\/\/doi.org\/10.3390\/ph16030415","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]}}}